Prostate Cancer
AlphaBet: Combination of Radium-223 and [17 7Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol).
December 7, 2022
Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques.
December 7, 2022
The LINC00852/miR-29a-3p/JARID2 axis regulates the proliferation and invasion of prostate cancer cell.
December 7, 2022
FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.
December 7, 2022
Accuracy of Prostate Cancer Screening Recommendations for High-Risk Populations on YouTube and TikTok
December 6, 2022
The Prostate Cancer Foundation Announces Inaugural $30 Million TACTICAL Awards Program for Innovative Prostate Cancer Research
December 6, 2022
Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
December 6, 2022
Prostate cancer screening with prostate-specific antigen (PSA) to men over 70 years old in an urban health zone, 2018-2020: A cross-sectional study.
December 6, 2022
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
December 6, 2022
Leading National Prostate Cancer Nonprofit Spearheads Influential HHS Moonshot Meeting
December 5, 2022
Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.
December 5, 2022
Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review.
December 5, 2022
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
December 5, 2022
From Concept to Regulatory Drug Approval: Lessons for Theranostics.
December 5, 2022
Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?
December 5, 2022